BioBridge Global Executive and Leadership Team

Norman Kalmin, the Medical Director & Chief Executive Officer & Qualtex Laboratories President at BioBridge Global, directs the overarching clinical and operational strategy for the organization. Kalmin oversees the integration of blood and tissue banking services, ensuring that QualTex Laboratories maintains rigorous quality standards for testing and processing. By aligning medical protocols with laboratory efficiency, the Medical Director & Chief Executive Officer & Qualtex Laboratories President drives the expansion of diagnostic capabilities across North American markets. This leadership role involves constant collaboration with the board to secure long-term sustainability for the foundation. Norman Kalmin monitors the performance of complex biological supply chains, ensuring that every tissue bank operates within strict regulatory frameworks. Through this focused approach, the executive ensures that the organization remains a leader in the life sciences sector, consistently delivering high-quality biological products to healthcare providers and patients.

John Youngdahl, the Senior Vice President & Chief Financial Officer at BioBridge Global, directs the financial strategy and fiscal health of the organization. Youngdahl oversees capital allocation, budgeting, and financial reporting to ensure that the company maintains the resources necessary for its mission-critical operations. By analyzing market trends and operational costs, the Senior Vice President & Chief Financial Officer drives the development of sustainable financial models for blood and tissue banking. This role involves collaborating with the executive team to evaluate investment opportunities in new technologies and laboratory infrastructure. John Youngdahl monitors the financial performance of all subsidiaries, ensuring that fiscal discipline supports the organization's growth objectives. Through the management of financial risk and the optimization of revenue streams, the executive secures the stability of the organization. Youngdahl provides the financial oversight required to sustain the organization's impact on the healthcare community.

Donna Respondek, the Executive Vice President & Chief Financial Officer at BioBridge Global, manages the comprehensive financial operations and strategic planning for the organization. Respondek oversees the development of long-term financial strategies that support the expansion of blood and tissue banking services. By directing the financial planning and analysis functions, the Executive Vice President & Chief Financial Officer ensures that the organization maintains a strong balance sheet while investing in critical laboratory capabilities. This leadership role involves working closely with the board to communicate financial performance and strategic priorities. Donna Respondek monitors the efficiency of financial processes, ensuring that resources are allocated effectively across all business units. Through the implementation of rigorous financial controls, the executive supports the organization's mission of providing life-saving biological products. Respondek ensures that the company remains financially resilient while pursuing its goals in the competitive biotechnology market.

Adrienne Mendoza, the Chief Operating Officer, BBG Advanced Therapies at BioBridge Global, manages the strategic development and execution of advanced therapeutic initiatives. Mendoza coordinates the scaling of specialized laboratory services, ensuring that the organization meets the evolving demands of the regenerative medicine market. By optimizing operational workflows, the Chief Operating Officer, BBG Advanced Therapies drives efficiency in the production of cellular therapies. This role requires close coordination with research teams to translate scientific breakthroughs into scalable clinical solutions. Adrienne Mendoza monitors the performance of advanced therapy programs, ensuring that all processes adhere to stringent safety and quality benchmarks. Through the implementation of robust operational strategies, the executive supports the broader mission of the organization, facilitating the delivery of innovative treatments to patients. Mendoza maintains a focus on operational excellence, ensuring that the advanced therapies division remains at the forefront of the biotechnology industry.

Geoffrey Kindt, the Interim Senior Vice President, Chief Operating Officer at BioBridge Global, directs the daily operational activities across the organization's diverse portfolio of blood and tissue banks. Kindt manages the allocation of resources to ensure that South Texas Blood & Tissue Center and other subsidiaries maintain consistent service levels. By streamlining internal processes, the Interim Senior Vice President, Chief Operating Officer drives improvements in supply chain reliability and operational throughput. This leadership position involves coordinating with department heads to align operational goals with the company's financial objectives. Geoffrey Kindt monitors regional performance metrics, ensuring that the organization effectively serves the needs of healthcare providers. Through the application of data-driven management techniques, the executive optimizes the performance of critical infrastructure. Kindt ensures that all operational units function in harmony, supporting the organization's commitment to providing essential biological resources to the community.

Mark Fite, the Executive Vice President BioBridge Global, Chief Operating Officer South Texas Blood and Tissue and QualTex Laboratories at BioBridge Global, manages the complex operational landscape of the organization's primary blood and tissue banking entities. Fite oversees the integration of laboratory testing services with blood collection operations to ensure seamless service delivery. By driving process improvements, the Executive Vice President BioBridge Global, Chief Operating Officer South Texas Blood and Tissue and QualTex Laboratories enhances the efficiency of the entire supply chain. This role involves managing large-scale logistics and ensuring that all facilities meet regulatory requirements for safety and quality. Mark Fite coordinates with other senior leaders to align operational strategies with the organization's long-term growth objectives. Through the implementation of standardized operating procedures, the executive ensures that the organization maintains its reputation for reliability and excellence in the biological services sector.

Taylor Audra, the Senior Vice President, BioBridge Global and Chief Operating Officer, South Texas Blood and Tissue at BioBridge Global, directs the operational strategy for the organization's blood collection and distribution network. Audra oversees the daily activities of the South Texas Blood & Tissue Center, ensuring that the facility meets the needs of regional healthcare providers. By optimizing collection logistics and donor engagement strategies, the Senior Vice President, BioBridge Global and Chief Operating Officer, South Texas Blood and Tissue drives the availability of essential blood products. This role involves coordinating with clinical teams to ensure that all operations adhere to the highest safety standards. Taylor Audra monitors performance metrics to identify opportunities for operational improvement and growth. Through the effective management of regional resources, the executive ensures that the organization maintains a reliable supply of biological materials for patient care.

Rachel Beddard, the Chief Medical Officer at BioBridge Global, directs the clinical governance and medical strategy for the organization. Beddard oversees the medical standards for blood and tissue banking, ensuring that all procedures align with current clinical best practices. By providing medical leadership, the Chief Medical Officer drives the development of protocols that enhance the safety and efficacy of biological products. This role involves collaborating with laboratory directors and clinical staff to ensure that the organization meets all regulatory and quality requirements. Rachel Beddard monitors emerging medical trends to inform the organization's strategic direction in the life sciences sector. Through the application of clinical expertise, the executive ensures that the organization maintains its commitment to patient safety and quality care. Beddard provides the medical oversight necessary to support the organization's mission of providing essential biological resources to the healthcare community.

Rachel-Louise Beddard, the Senior Vice President, Chief Medical Officer at BioBridge Global, manages the clinical oversight and medical policy for the organization's diverse laboratory and banking operations. Beddard directs the implementation of medical quality assurance programs, ensuring that all tissue and blood products meet the highest standards of safety. By leading the medical team, the Senior Vice President, Chief Medical Officer drives the integration of clinical research into the organization's operational framework. This role involves working with external regulatory bodies to ensure compliance with medical standards. Rachel-Louise Beddard monitors the clinical performance of all subsidiaries, providing guidance on complex medical issues that impact service delivery. Through the application of deep clinical knowledge, the executive supports the organization's mission of advancing life-saving biological solutions. Beddard ensures that the organization remains a trusted partner for healthcare providers by maintaining rigorous medical standards across all operations.